Evidence map›Paper›PMID 39342013›Full record

ArticleScientific reports2024

Single-hit genome editing optimized for maturation in B cells redirects their specificity toward tumor antigens.

Natsuko Ueda, Marine Cahen, Jenny Leonard, Laurent Deleurme, Stéphane Dreano, Christophe Sirac, Anne Galy, Jérôme Moreaux, Yannic Danger, Michel Cogné

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natsuko Ueda *INSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France.
Marine Cahen *INSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France.
Jenny LeonardINSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France.
Laurent DeleurmeINSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France.
Stéphane DreanoCNRS-UMR 6290, Institute of Genetics and Development, 35000, Rennes, France.
Christophe SiracControl of the B-cell Response & Lymphoproliferation, INSERM U1262, CNRS UMR 7276, Limoges University, 87025, Limoges, France.
Anne GalyIntegrare Research Unit UMR_S951, Inserm, Genethon, Université Paris-Saclay, University of Evry, 91000, Evry, France.
Jérôme MoreauxCNRS-UM UMR 9002, Institute of Human Genetics, 34090, Montpellier, France.
Yannic DangerINSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France.
Michel CognéINSERM U 1236, University of Rennes 1, Etablissement Français du Sang, 35000, Rennes, France. michel.cogne@inserm.fr.

Funding

Fondation ARC PGA1 RF20180207070
6 · The paper itself

Abstract

T-cell-based adoptive immunotherapy is a new pillar of cancer care. Tumor-redirected B cells could also contribute to therapy if their manipulation to rewire immunoglobulin (Ig) genes is mastered. We designed a single-chain Ig-encoding cassette ("scFull-Ig") that redirects antigen specificity when inserted at a single position of the IgH locus. This design, which places combined IgH and IgL variable genes downstream of a pVH promoter, nevertheless preserves all Ig functional domains and the intrinsic mechanisms that regulate expression from the IgM B cell receptor (BCR) expression to Ig secretion, somatic hypermutation and class switching. This single-locus editing provides an efficient and safe strategy to both disrupt endogenous Ig expression and encode a new Ig paratope. As a proof of concept, the functionality of scFull BCR and/or secreted Ig was validated against two different classical human tumor antigens, HER2 and hCD20. Once validated in cell lines, the strategy was extended to primary B cells, confirming the successful engineering of BCR and Ig expression and the ability of scFull-Ig to undergo further class switching. These results further pave the way for future B cell-based adoptive immunotherapy and strategies to express a therapeutic mAb with a variety of switched H-chains that provide complementary functions.

Indexed as

Antigens, NeoplasmB-LymphocytesGene EditingReceptors, Antigen, B-CellErb-b2 Receptor Tyrosine KinasesHumansImmunoglobulin Class SwitchingImmunotherapy, AdoptiveAntigens, NeoplasmERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Antigen, B-Cell

Identifiers

PMID39342013
PMCPMC11438885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.